[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636768":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":23,"centralContacts":23,"locations":23,"responsibleParty":24,"collaborators":23,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":32,"eligibilityCriteria":33,"healthyVolunteers":28,"sex":34,"minAge":35,"maxAge":36,"enrollmentInfo":37,"targetDuration":23,"studyType":40,"phases":41,"briefSummary":43,"conditions":44,"keywords":50,"overallStatus":59,"whyStopped":23,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":23},{"fullName":5,"class":6},"Nakhia Impex LLC","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"HA35 Topical Gel Intervention Group","EXPERIMENTAL","Participants will receive a single topical application of 10% high-concentration 35 kDa hyaluronan (HA35 gel) to the affected skin area. Pain intensity, analgesic onset, duration, and local safety will be evaluated.",[13],"Device: 10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Analgesic Gel",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","10% High-Concentration 35 kDa Hyaluronan (HA35) Topical Analgesic Gel","A topical, non-pharmacological gel containing 10% high-concentration 35 kDa hyaluronan fragment. It is applied topically to the affected skin area to relieve herpes zoster-associated pain, reduce inflammation, and improve local tolerability.",[9],[21,22],"HA35 Zoster Pain Gel","HA35 Analgesic Gel",null,{"type":25,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100636768","efficacy-and-safety-of-high-concentration-35-kda-hyaluronan-gel-for-herpes-zoster-associated-pain-100636768",false,"NCT07569978","Efficacy and Safety of High-Concentration 35 kDa Hyaluronan Gel for Herpes Zoster-Associated Pain","A Prospective, Single-Arm, Open-Label Pilot Clinical Study to Evaluate the Efficacy and Safety of Topical 10% High-Concentration 35 kDa Hyaluronan (HA35) Gel in Subjects With Herpes Zoster-Associated Pain","HA35-HZ","Inclusion Criteria:\n\n* Age 18-85 years, male or female\n* Clinically diagnosed with herpes zoster-associated pain (acute ZAP or PHN)\n* Baseline pain NRS score ≥5\n* Ability to understand and complete NRS assessments\n* Signed written informed consent\n\nExclusion Criteria:\n\n* Acute bacterial skin infection at the application site\n* Use of topical analgesics or antiviral therapy within 24 hours\n* Systemic analgesic use within 6 hours\n* Known hypersensitivity to hyaluronan or gel components\n* Pregnant or lactating women\n* Severe systemic disease or malignant tumor","ALL","18 Years","85 Years",{"count":38,"type":39},30,"ESTIMATED","INTERVENTIONAL",[42],"NA","This is a prospective, single-arm, open-label, pilot clinical study to evaluate the efficacy and safety of topical 10% high-concentration 35 kDa hyaluronan (HA35) gel in subjects with herpes zoster-associated pain (ZAP). Eligible participants will receive a single topical application of the study gel. The primary objective is to assess rapid pain reduction within 2 minutes and 24hours after application. Secondary objectives include evaluation of analgesic duration, local tolerability, erythema improvement, and overall safety throughout the observation period. This is a minimal-risk, non-pharmacological supportive care intervention.",[45,46,47,48,49],"Herpes Zoster","Zoster-Associated Pain","Postherpetic Neuralgia","Neuropathic Pain","Acute Pain",[51,52,53,54,45,55,47,48,56,57,58],"Hyaluronan","35 kDa Hyaluronan","HA35","Topical Gel","Zoster Pain","Analgesia","Non-pharmacological Intervention","Pilot Clinical Study","NOT_YET_RECRUITING","2026-05-05",{"date":62,"type":63},"2026-05-08","ACTUAL",{"date":65,"type":39},"2026-05-01",{"date":67,"type":39},"2026-07-10",{"name":5,"class":6}]